Literature DB >> 1328361

Effect of local intra-arterial NG-monomethyl-L-arginine in patients with hypertension: the nitric oxide dilator mechanism appears abnormal.

A Calver1, J Collier, S Moncada, P Vallance.   

Abstract

OBJECTIVE: There is indirect evidence that the nitric oxide system may be impaired in hypertensive patients. The objective of this study was to examine basal nitric oxide-mediated dilation in hypertensive patients.
DESIGN: The forearm blood flow (FBF) response to noradrenaline and NG-monomethyl-L-arginine (L-NMMA), a stereospecific inhibitor of nitric oxide synthesis, was compared in seven untreated hypertensive patients and 17 normotensive controls.
METHODS: Drugs were infused locally into the brachial artery and FBF measured using venous occlusion plethysmography.
RESULTS: In normotensives noradrenaline (60, 120 and 240 pmol/min) and L-NMMA (1,2 and 4 mumol/min) produced similar reductions in resting FBF. In the hypertensives L-NMMA was significantly less effective than noradrenaline, such that the threshold dose for L-NMMA vasoconstriction was increased and the overall response to L-NMMA reduced. Furthermore, when noradrenaline was used as an internal control there was a significant negative relationship between the response to L-NMMA and blood pressure. When the responses to L-NMMA and noradrenaline were compared between groups, the response to L-NMMA was significantly less in hypertensives compared with normotensives, whereas there was no statistical difference in the response to noradrenaline between the two groups.
CONCLUSIONS: The results suggest an abnormality of basal nitric oxide-mediated dilation in the forearm arteriolar bed of patients with untreated essential hypertension.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1328361

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  43 in total

Review 1.  Nitric oxide: discovery and impact on clinical medicine.

Authors:  S Moncada
Journal:  J R Soc Med       Date:  1999-04       Impact factor: 5.344

Review 2.  Endothelial nitric oxide in humans in health and disease.

Authors:  P Vallance; A Hingorani
Journal:  Int J Exp Pathol       Date:  1999-12       Impact factor: 1.925

Review 3.  Endothelial function and nitric oxide: clinical relevance.

Authors:  P Vallance; N Chan
Journal:  Heart       Date:  2001-03       Impact factor: 5.994

Review 4.  Effects of antihypertensive drugs on endothelial dysfunction: clinical implications.

Authors:  Stefano Taddei; Agostino Virdis; Lorenzo Ghiadoni; Isabella Sudano; Antonio Salvetti
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 5.  Venous occlusion plethysmography in cardiovascular research: methodology and clinical applications.

Authors:  I B Wilkinson; D J Webb
Journal:  Br J Clin Pharmacol       Date:  2001-12       Impact factor: 4.335

6.  Nitric oxide activity in childhood hypertension.

Authors:  C D Goonasekera; V Shah; D D Rees; M J Dillon
Journal:  Arch Dis Child       Date:  1997-07       Impact factor: 3.791

Review 7.  Therapeutic role of bosentan in hypertension: lessons from the model of perinephritic hypertension.

Authors:  J E Donckier
Journal:  Heart Fail Rev       Date:  2001-12       Impact factor: 4.214

8.  Sympathetic activation and nitric oxide function in early hypertension.

Authors:  Alfredo Gamboa; Luis E Okamoto; André Diedrich; Leena Choi; David Robertson; Ginnie Farley; Sachin Paranjape; Italo Biaggioni
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-01-27       Impact factor: 4.733

9.  Arterial contractions induced by cumulative addition of calcium in hypertensive and normotensive rats: influence of endothelium.

Authors:  M Kähönen; P Arvola; X Wu; I Pörsti
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-06       Impact factor: 3.000

Review 10.  Endothelial nitric oxide synthase polymorphisms and hypertension.

Authors:  Aroon D Hingorani
Journal:  Curr Hypertens Rep       Date:  2003-02       Impact factor: 5.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.